Skip to content

Erythropoiesis-stimulating agent (ESA) monitoring panel

Published: August 9, 2026Updated: August 16, 2026

This test measures blood and urine markers to check how your body responds to erythropoiesis-stimulating agents (ESAs), medications used to stimulate red blood cell production.

Quick summary

["ESAs help manage conditions like anemia, but monitoring helps ensure safety and effectiveness."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
71457-6
Short code
ERYTHROPOIESISSTIMULATINGAGENTPANEL
Synonyms
—
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
esrd
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

Your blood sample will be analyzed for key indicators of red blood cell activity and ESA effects. This includes checking levels of iron, vitamin B12, folate, and red blood cell counts to ensure proper production and function. Urine tests may also be included to assess kidney function and ESA metabolism.

Why It’s Done

Doctors use this panel to monitor how well your body is responding to ESA treatment, detect potential side effects (like high blood pressure or iron overload), and adjust medications as needed. It helps balance the benefits of increased red blood cells with risks like blood clots or iron toxicity.

Common Conditions Monitored

This panel is typically used in patients with chronic kidney disease, cancer-related anemia, or other conditions requiring ESA therapy. It ensures your treatment supports your health without causing complications.

Sample Collection Process

Blood and urine samples are collected during a routine clinic visit. Blood is drawn from a vein, while urine may be collected over a set period (e.g., 24 hours). The samples are sent to a lab for analysis to measure specific markers.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Abnormal results may indicate ineffective ESA treatment, kidney issues, or side effects like high iron stores or blood clots. Close monitoring helps prevent complications and personalizes your care plan. Always discuss results with your healthcare provider.

Short name

ESA Monitoring Panel

Frequently asked questions

What does this test check for?
This panel evaluates red blood cell production, iron metabolism, kidney function, and how your body processes ESA medications. It includes blood tests (like hemoglobin, iron levels) and urine tests (if applicable) to assess overall response and safety.
Can I eat or drink before this test?
For blood tests, you may eat normally, but avoid heavy meals before drawing. For urine tests (if applicable), follow your provider’s instructions—often fasting or specific timing is required. Always confirm with your lab or doctor.
How long does it take to get results?
Results are typically available within 1–3 business days, depending on the lab. Your healthcare provider will discuss them with you during your follow-up visit.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy